Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1937 1
1945 1
1946 4
1947 11
1948 12
1949 10
1950 16
1951 14
1952 18
1953 24
1954 18
1955 14
1956 18
1957 18
1958 9
1959 14
1960 30
1961 21
1962 25
1963 59
1964 103
1965 70
1966 67
1967 55
1968 82
1969 81
1970 68
1971 73
1972 86
1973 78
1974 98
1975 99
1976 64
1977 117
1978 88
1979 113
1980 85
1981 107
1982 98
1983 104
1984 118
1985 110
1986 116
1987 122
1988 135
1989 136
1990 125
1991 125
1992 115
1993 89
1994 111
1995 95
1996 96
1997 111
1998 96
1999 88
2000 97
2001 96
2002 134
2003 126
2004 148
2005 197
2006 210
2007 241
2008 223
2009 241
2010 268
2011 254
2012 310
2013 344
2014 381
2015 439
2016 476
2017 443
2018 431
2019 420
2020 445
2021 511
2022 479
2023 460
2024 461
2025 451
2026 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,174 results

Results by year

Filters applied: . Clear all
Page 1
[Myelofibrosis: A review].
Genthon A, Killian M, Mertz P, Cathebras P, Gimenez De Mestral S, Guyotat D, Chalayer E. Genthon A, et al. Rev Med Interne. 2021 Feb;42(2):101-109. doi: 10.1016/j.revmed.2020.08.018. Epub 2020 Nov 23. Rev Med Interne. 2021. PMID: 33243417 Review. French.
Myelofibrosis is a BCR-ABL1-negative chronic myeloproliferative neoplasm that includes primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. ...Complications as thromboembolic or hemorrhagic even …
Myelofibrosis is a BCR-ABL1-negative chronic myeloproliferative neoplasm that includes primary myelofibrosis, post-polycythemi …
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B, Schaefer JK, Mercer J, Talpaz M. Garmezy B, et al. Blood Rev. 2021 Jan;45:100691. doi: 10.1016/j.blre.2020.100691. Epub 2020 Apr 7. Blood Rev. 2021. PMID: 32354563 Review.
Although understanding of the pathogenesis and molecular biology of primary myelofibrosis continues to improve, treatment options are limited, and several biological features remain unexplained. ...In this review, we outline what is known about the disease pathogenesis, di …
Although understanding of the pathogenesis and molecular biology of primary myelofibrosis continues to improve, treatment options are …
Cytopenic myelofibrosis: prevalence, relevance, and treatment.
Vachhani P, Verstovsek S, Bose P. Vachhani P, et al. Expert Opin Pharmacother. 2023 Jun;24(8):901-912. doi: 10.1080/14656566.2023.2203318. Epub 2023 Apr 17. Expert Opin Pharmacother. 2023. PMID: 37070147 Review.
INTRODUCTION: Cytopenic myelofibrosis is increasingly recognized as a phenotype of myelofibrosis presenting with low blood counts, lower driver mutation allele burden, increased likelihood of arising de novo, i.e. primary myelofibrosis, greater genomic comple …
INTRODUCTION: Cytopenic myelofibrosis is increasingly recognized as a phenotype of myelofibrosis presenting with low blood cou …
Prognostic and Predictive Models in Myelofibrosis.
Mora B, Bucelli C, Cattaneo D, Bellani V, Versino F, Barbullushi K, Fracchiolla N, Iurlo A, Passamonti F. Mora B, et al. Curr Hematol Malig Rep. 2024 Oct;19(5):223-235. doi: 10.1007/s11899-024-00739-6. Epub 2024 Aug 24. Curr Hematol Malig Rep. 2024. PMID: 39179882 Free PMC article. Review.
PURPOSE OF REVIEW: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). ...For SMF, OS estimates should be calculated by the specific MYSEC-PM (MYelofibrosis SECondary-prognostic model). Information on the prognostic role o …
PURPOSE OF REVIEW: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). ...For SMF, OS est …
Myelofibrosis biology and contemporary management.
Gangat N, Tefferi A. Gangat N, et al. Br J Haematol. 2020 Oct;191(2):152-170. doi: 10.1111/bjh.16576. Epub 2020 Mar 20. Br J Haematol. 2020. PMID: 32196650 Review.
Myelofibrosis is an enigmatic myeloproliferative neoplasm, despite noteworthy strides in understanding its genetic underpinnings. ...Our review serves to synopsise current appreciation of the pathogenesis of myelofibrosis together with emerging management strategies …
Myelofibrosis is an enigmatic myeloproliferative neoplasm, despite noteworthy strides in understanding its genetic underpinnings. ... …
Management of Myelofibrosis-Related Cytopenias.
Bose P, Verstovsek S. Bose P, et al. Curr Hematol Malig Rep. 2018 Jun;13(3):164-172. doi: 10.1007/s11899-018-0447-9. Curr Hematol Malig Rep. 2018. PMID: 29796726 Review.
PURPOSE OF REVIEW: Cytopenias, particularly anemia, are frequently encountered in patients with myelofibrosis. Management of cytopenias in myelofibrosis can be very challenging because current therapeutic interventions are only of modest efficacy and ruxolitinib, th …
PURPOSE OF REVIEW: Cytopenias, particularly anemia, are frequently encountered in patients with myelofibrosis. Management of cytopeni …
Momelotinib for the treatment of myelofibrosis with anemia.
Tremblay D, Mesa R. Tremblay D, et al. Future Oncol. 2022 Jun;18(20):2559-2571. doi: 10.2217/fon-2022-0276. Epub 2022 May 23. Future Oncol. 2022. PMID: 35603634 Review.
Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, debilitating constitutional symptoms and bone marrow failure. ...This review explores the preclinical rationale, clinical trial data and future role of momelotinib in the evolving therapeutic lan …
Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, debilitating constitutional symptoms and bone marrow fa …
Managing patients with myelofibrosis and thrombocytopenia.
Yilmaz M, Verstovsek S. Yilmaz M, et al. Expert Rev Hematol. 2022 Mar;15(3):233-241. doi: 10.1080/17474086.2022.2057296. Epub 2022 Mar 29. Expert Rev Hematol. 2022. PMID: 35316110 Review.
INTRODUCTION: Given the progressive nature of myelofibrosis, the incidence of thrombocytopenia increases over time. Furthermore, approved drugs ruxolitinib and fedratinib, induce thrombocytopenia. Hence, treatment of myelofibrosis patients with low platelet counts i …
INTRODUCTION: Given the progressive nature of myelofibrosis, the incidence of thrombocytopenia increases over time. Furthermore, appr …
Myelofibrosis: clinicopathologic features, prognosis, and management.
O'Sullivan JM, Harrison CN. O'Sullivan JM, et al. Clin Adv Hematol Oncol. 2018 Feb;16(2):121-131. Clin Adv Hematol Oncol. 2018. PMID: 29741513 Review.
Myelofibrosis is one of the BCR-ABL-negative clonal disorders that collectively are known as myeloproliferative neoplasms (MPNs). ...This review provides further detail regarding the clinical features, pathogenesis, risk stratification, and current management of myelofi …
Myelofibrosis is one of the BCR-ABL-negative clonal disorders that collectively are known as myeloproliferative neoplasms (MPNs). ... …
Primary myelofibrosis and its targeted therapy.
Shantzer L, Berger K, Pu JJ. Shantzer L, et al. Ann Hematol. 2017 Apr;96(4):531-535. doi: 10.1007/s00277-016-2785-9. Epub 2016 Aug 19. Ann Hematol. 2017. PMID: 27539616 Review.
Primary myelofibrosis is a unique entity among BCR-ABL-negative myeloproliferative diseases, manifesting as bone marrow fibrosis and pancytopenia. ...The "bad seeds in bad soil" theory illustrates the orchestrating efforts of hematopoietic stem cells, stromal cells, and th …
Primary myelofibrosis is a unique entity among BCR-ABL-negative myeloproliferative diseases, manifesting as bone marrow fibrosis and …
11,174 results
You have reached the last available page of results. Please see the User Guide for more information.